Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs

Siddarth Raman; James E. Polli

doi:10.1016/j.ijpharm.2016.04.013

Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs

Siddarth Raman, James E. Polli

In: International Journal of Pharmaceutics · 2016 · vol. 506(1-2) , pp. 110–115 · doi:10.1016/j.ijpharm.2016.04.013 · PMID:27067239 · W2330580624

article OA: closed CC0 ⤵ 1 in-corpus citation

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This paper investigates methods to enhance the bioavailability of BCS Class II drugs by predicting and optimizing positive food effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Determination of Danazol in Plasma by High Performance Liquid Chromatography 1989

Cited by (1)

The in vivo predictive dissolution for immediate release dosage of donepezil and danazol, BCS class IIc drugs, with the GIS and the USP II with biphasic dissolution apparatus 2019

References (25)

Determination of Danazol in Plasma by High Performance Liquid Chromatography via openalex
doi:10.1016/s0021-9258(19)70749-2 via openalex
doi:10.1023/a:1013319408893 via openalex
doi:10.1021/js960085v via openalex
doi:10.1021/bi00460a012 via openalex
doi:10.1007/s11095-008-9569-4 via openalex
doi:10.1002/jps.2600750313 via openalex
doi:10.1016/s0939-6411(99)00070-3 via openalex
doi:10.1002/j.1552-4604.1991.tb03658.x via openalex
doi:10.1016/j.ijpharm.2011.03.002 via openalex
doi:10.1093/jat/28.1.63 via openalex
doi:10.1016/s1056-8719(00)00107-6 via openalex
doi:10.1016/j.ejps.2004.08.003 via openalex
doi:10.1007/s11095-006-9054-x via openalex
doi:10.1208/s12248-008-9025-8 via openalex
doi:10.2165/00003088-200645120-00006 via openalex
doi:10.33786/jcpr.2011.v01i04.003 via openalex
doi:10.1016/b978-0-12-134550-1.50007-1 via openalex
doi:10.1002/jps.20691 via openalex
doi:10.1016/s0928-0987(01)00169-5 via openalex
doi:10.1113/jphysiol.1982.sp014383 via openalex
doi:10.1002/jps.20767 via openalex
doi:10.1016/j.ijpharm.2011.08.032 via openalex
doi:10.1023/a:1016212804288 via openalex
doi:10.1159/000115345 via openalex

Cited by (1)

The in vivo predictive dissolution for immediate release dosage of donepezil and danazol, BCS class IIc drugs, with the GIS and the USP II with biphasic dissolution apparatus 2019

Source provenance

openalex: last seen: 2026-05-11T06:27:45.971503+00:00
unpaywall: last seen: 2026-06-13T06:42:57.164913+00:00

License: CC0 · commercial use OK

[1] Determination of Danazol in Plasma by High Performance Liquid Chromatography 1989